Desvenlafaxine Tablet, Extended Release
Product Images NDC 71335-1815

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71335-1815). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Des Structure)

Chemical Structure (Des Structure)
Chemical structure of desvenlafaxine showing its molecular components including aromatic rings, hydroxyl groups, and carboxylic acid groups, along with a water molecule (H2O).*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A forest plot chart showing the geometric mean ratio with 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of Desvenlafaxine 100 mg extended-release tablets. The chart compares these values for patients with varying degrees of renal and hepatic impairment, as well as by gender and age groups, relative to reference values.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A plot showing the geometric mean ratio (90% confidence interval) for pharmacokinetic changes due to CYP3A4 inhibitors, specifically ketoconazole, relative to a reference. The chart includes Cmax and AUC values with corresponding confidence intervals and numeric labels on the right side.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A forest plot chart showing the geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters Cmax and AUC of various interacting drugs (Desipramine, Midazolam, Tamoxifen, Aripiprazole) when coadministered with different doses of Desvenlafaxine (50mg, 100mg, 400mg). It compares CYP2D6, CYP3A4, and combined substrates, highlighting changes relative to reference values.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A Kaplan-Meier plot showing the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Desvenlafaxine Extended-Release Tablets 50 mg (solid blue line) versus placebo (dashed red line). The graph illustrates relapse trends up to approximately 180 days.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A Kaplan-Meier curve showing the estimated proportion of patients with relapse over time (days from randomization) for Desvenlafaxine Extended-Release Tablets and placebo. The x-axis represents time to relapse in days up to 200, and the y-axis shows the percentage of patients with relapse up to 50%. Desvenlafaxine is represented by a solid blue line, and placebo by a dashed red line, indicating higher relapse rates with placebo over time.*
FDA Label Image

Label (Lbl713351815)

Label (Lbl713351815)
Desvenlafaxine ER 100 mg tablet label by Bryant Ranch Prepack. The label notes comparison to Pristiq 100 mg tablet and includes storage instructions at 20°-25°C (68°-77°F). It also displays lot number 1523487, RX only designation, and a barcode with NDC 71335-1815-1. The package contains 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.